Glycan Therapeutics possesses a unique patented technology to synthesize heparin and heparan sulfate oligosaccharides for medical uses. Glycan Therapeutics (GT) is developing new drug therapies based on a novel synthetic carbohydrate technology platform. The platform technology can be used to synthesize an anticoagulant drug, like synthetic heparin, as well as design heparin-like oligosaccharides for research and development for other medical applications. We are the leader in the development of enzymatically synthesized sulfated oligosaccharides for a variety of indications. While aiming to develop a cost-effective method to prepare synthetic heparin, the company is also preparing a wide ranges of homogeneous heparin oligosaccharide products for researchers to investigate the role of these products in vascular biology, developmental biology and infectious diseases. The company has been supported by SBIR contracts from National Cancer Institute.
We are the leader in the synthesis of heparin sulfate oligosaccharides and oligosaccharide derivatives. We offer the highest quality products at an affordable price including: Custom synthesis of homogeneous heparin and heparin sulfate oligosaccharides with a wide range of sizes and sulfation patterns for your research needs.
Glycan Therapeutics LLC has not received any reviews.
Glycan Therapeutics LLC has not received any endorsements.